Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and telaprevir (VX 950) in human plasma by LC-MS/MS

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 877, Issue 31, 2009, Pages 4001-4006

  Farnik, Harald ^a   El Duweik, Juliane ^a   Welsch, Christoph ^a   Sarrazin, Christoph ^a   Lötsch, Jörn ^a   Zeuzem, Stefan ^a   Geisslinger, Gerd ^a   Schmidt, Helmut ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Antivirals; Boceprevir; Tandem mass spectrometry; Telaprevir

Indexed keywords

ANTIVIRALS; CONCENTRATION RANGES; HEPATITIS C VIRUS; HIGHLY SENSITIVE; HUMAN PLASMAS; INJECTION VOLUME; INTERNAL STANDARDS; LC-MS/MS; LOWER LIMIT OF QUANTIFICATIONS; MOBILE PHASE; PLASMA SAMPLES; PRECIPITATION PROCESS; PROTEASE INHIBITOR; RUNTIMES; SAMPLE PREPARATION; TANDEM MASS SPECTROMETRY;

CALIBRATION; MASS SPECTROMETERS; MASS SPECTROMETRY; PLASMA (HUMAN); PRECIPITATION (CHEMICAL);

PLASMAS;

BOCEPREVIR; PROTEINASE INHIBITOR; TELAPREVIR;

ACCURACY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STABILITY; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PARTICLE SIZE; PRECIPITATION; PRIORITY JOURNAL; REPRODUCIBILITY;

ANTIVIRAL AGENTS; CHROMATOGRAPHY, LIQUID; HEPACIVIRUS; HUMANS; OLIGOPEPTIDES; PEPTIDE HYDROLASES; PROLINE; PROTEASE INHIBITORS; REFERENCE STANDARDS; TANDEM MASS SPECTROMETRY;

HEPATITIS C VIRUS;

EID: 72049107852     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2009.10.013     Document Type: Article

References (11)

1. Poynard T., Yuen M.F., Ratziu V., and Lai C.L. Lancet 362 (2003) 2095
2. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales Jr. F.L., Häussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., and Yu J. N. Engl. J. Med. 347 (2002) 975
3. Chen S.H., and Tan S.L. Curr. Med. Chem. 12 (2005) 2317
4. Malcolm B.A., Liu R., Lahser F., Agrawal S., Belanger B., Butkiewicz N., Chase R., Gheyas F., Hart A., Hesk D., Ingravallo P., Jiang C., Kong R., Lu J., Pichardo J., Prongay A., Skelton A., Tong X., Venkatraman S., Xia E., Girijavallabhan V., and Njoroge F.G. Antimicrob. Agents Chemother. 50 (2006) 1013
5. S. Susser, C. Welsch, Y. Wang, M. Zettler, F.S. Domingues, U. Karey, E. Hughes, R. Ralston, X. Tong, E. Herrmann, S. Zeuzem, C. Sarrazin, Hepatology. (2009) Aug 4. [Epub ahead of print].
6. Kwo P., Lawitz E., McCone J., Schiff E., Vierling J., Pound D., Davis M., Galati J., Gordon S., Ravendhran N., Rossaro L., Anderson F., Jacobson I., Rubin R., Koury K., Brass C., Chaudhri E., and Albrecht J. J. Hepatol. 50 (2009) S4
7. Hézode C., Forestier N., Dusheiko G., Ferenci P., Pol S., Goeser T., Bronowicki J.P., Bourlière M., Gharakhanian S., Bengtsson L., McNair L., George S., Kieffer T., Kwong A., Kauffman R.S., Alam J., Pawlotsky J.M., and Zeuzem S. N. Engl. J. Med. 360 (2009) 1839
8. McHutchison J.G., Everson G.T., Gordon S.C., Jacobson I.M., Sulkowski M., Kauffman R., McNair L., Alam J., and Muir A.J. N. Engl. J. Med. 360 (2009) 1827
9. FDA. Guidance for Industry-Bioanalytical Method Validation (2001)
10. Sarrazin C., Kieffer T.L., Bartels D., Hanzelka B., Müh U., Welker M., Wincheringer D., Zhou Y., Chu H.M., Lin C., Weegink C., Reesink H., Zeuzem S., and Kwong A.D. Gastroenterology 132 (2007) 1767
11. Wang G., Hsieh Y., Cheng K.C., Morrison R.A., Venkatraman S., Njoroge F.G., Heimark L., and Korfmacher W.A. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 852 (2007) 92